Zentalis Pharmaceuticals, Inc. (ZNTL)

CIK 0001725160 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-08-06) · 99.1 · 99.2
Q1-2026 8-K (2026-05-12) · 99.1 · 99.2
Latest FY-2025 8-K (2026-03-26) · 99.1
Q3-2025 8-K (2025-11-10) · 99.1 · 99.2
Q2-2025 8-K (2025-08-06) · 99.1 · 99.2
Q1-2025 8-K (2025-05-14) · 99.1
FY-2024 8-K (2025-03-26) · 99.1
Q3-2024 —
Q2-2024 8-K (2024-08-09) · 99.1
Q1-2024 8-K (2024-05-07) · 99.1
FY-2023 8-K (2024-02-27) · 99.1
Q3-2023 8-K (2023-11-06) · 99.1 · 99.2

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Audit Information
—
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations
Condensed Consolidated Statements of Comprehensive (loss) Income (unaudited)
—
Condensed Consolidated Statements of Comprehensive Income (loss) (unaudited)
—
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Stockholders’ Equity
—
Consolidated Statements Stockholders' Equity
—
Notes
Accrued Expenses
Business Combinations
Commitments and Contingencies
Cybersecurity Risk Management and Strategy Disclosure
—
Employee Savings Plan
—
Fair Value Measurement
Income Taxes
—
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Interim Unaudited Financial Statements
—
Net Income (loss) Per Common Share
—
Net Loss Per Common Share
Organization and Business
Pay Vs Performance Disclosure
Prepaid Expenses and Other Assets
Property and Equipment, Net
Recurium Ip Holdings, Llc Agreement
—
Related Party Disclosures
Related Party Transaction
—
Restructuring
Segment Reporting and Disaggregation of Relevant Expense Captions
Significant Transactions
Stockholders' Equity
Subsequent Events
Summary of Significant Accounting Policies
—